Mydecine InnovationsNEO: MYCO
Canadian biotech using AI-assisted drug discovery at the University of Alberta to develop novel psilocybin and MDMA analogues for mental health and addiction treatment. Pipeline compounds MYCO-003 through MYCO-007 represent a library of psychedelic-inspired molecules at preclinical stage.
Development Programmes
2MYCO-001
PsilocybinSmoking cessation / PTSD
Programme Tracker
Substance Use Disorders (SUD)
Phase 2b multi-site placebo-controlled trial; PI: Dr. Matthew Johnson (Johns Hopkins); sites: Hopkins, NYU, UAB; IND filed with FDA
Milestones
Phase II started
CompletedActual: Sep 1, 2022
Phase 2b seamless smoking cessation trial initiated with Johns Hopkins partnership; IRB conditional approval received
Why it matters: MYCO-001 is a 99.9% pure natural-source psilocybin developed in partnership with Johns Hopkins' Dr. Matthew Johnson — the researcher behind the landmark 2022 JAMA Psychiatry smoking cessation study (80% abstinence at 12 months). The Phase 2b replicates this design at multiple sites.
Watch next: Phase 2b 3-month and 6-month abstinence primary endpoint results
Recorded Events
Sep 1, 2022: Phase II started
PTSD
Phase 2a in veteran PTSD; partnership with Combat Stress (UK) and King's College London; PI: Dr. Rakesh Jetly
Milestones
Phase II started
CompletedActual: Jan 24, 2022
Partnership with Combat Stress and King's College London announced for veteran PTSD trial
Why it matters: Dr. Rakesh Jetly is the leading clinical researcher for psilocybin PTSD trials in veterans. Combat Stress is the UK's leading veteran mental health charity. This partnership brings credibility and access to a high-burden, treatment-resistant PTSD population.
Watch next: Phase 2a results in veteran PTSD cohort
Recorded Events
Jan 24, 2022: Phase II started
MYCO-004
Substance use disorder / smoking cessation
Programme Tracker
Substance Use Disorders (SUD)
Preclinical development of patch-delivered tryptamine formulation for substance use disorder and smoking cessation
Milestones
Pre-clinical completed
In progressWhy it matters: MYCO-004 is a transdermal tryptamine — distinct from MYCO-001's oral psilocybin. Patch delivery could enable controlled, slow-release dosing (potentially sub-perceptual) without the 4–6 hour oral psychedelic session, expanding access to patients unwilling or unable to undergo full psychedelic sessions.
Watch next: Preclinical PK/PD data and indication selection for IND
Quick Facts
- Type
- Public Biotech
- Ticker
- NEO: MYCO
- Lead Stage
- Phase II
- Website
- Visit